← Leaderboards
Mary A Dooley
University Of North Carolina Chapel Hill
$3,689,855
Attributed
$3,689,855
Total exposure
10
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $689 · FY2005–08$1K$750$500$250$0
'05
'06
'07
'08
Funding mix
By agency
NIH$3,689,855 · 10
By mechanism
M01$3,589,855 · 9
R55$100,000 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Kim L Isaacs$2,243,938
- William R Meyer$1,559,955
- David A Savitz$11,328,248
- Zhi Liu$9,856,482
- Jo-David J Fine$1,378,252
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationDrug Screening /EvaluationArthritis TherapyClinical Trial Phase INonsteroidal Antiinflammatory AgentAntiarthritic AgentRheumatoid ArthritisSystemic Lupus ErythematosusConnective Tissue Disorder ChemotherapyClinical TrialsAntirheumatic AgentsFemaleDrug InteractionsThiazinesPhenylacetatesPlacebosNephritisCombination ChemotherapyAgingEgg /OvumChemopreventionDrug Adverse Effect
Grant awards (28)
SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS REGISTRY FOR ATHEROSCLEROSIS$689
M01 · FY2008 · RR · contact PI
SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS REGISTRY FOR ATHEROSCLEROSIS$187
M01 · FY2007 · RR · contact PI
SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS REGISTRY FOR ATHEROSCLEROSIS$248
M01 · FY2006 · RR · contact PI
SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS REGISTRY FOR ATHEROSCLEROSIS$629
M01 · FY2005 · RR
THREE DOSES OF MELOXICAM W/ DICLOFENAC FOR RHEUMATOID ARTHRITIS$190,747
M01 · FY2002 · RR
RO32 3555 AS ADJUNCT TO BACKGROUND THERAPY IN RHEUMATOID ARTHRITIS$190,747
M01 · FY2002 · RR
ORAL CONTRACEPTIVES AND HORMONAL REPLACEMENT IN SLE$190,747
M01 · FY2002 · RR
PRESERVING OVARIAN FUNCTION IN LUPUS NEPHRITIS$190,747
M01 · FY2002 · RR
ORAL CONTRACEPTIVES AND HORMONAL REPLACEMENT IN SLE$294,555
M01 · FY2001 · RR
RO32 3555 AS ADJUNCT TO BACKGROUND THERAPY IN RHEUMATOID ARTHRITIS$294,555
M01 · FY2001 · RR
PRESERVING OVARIAN FUNCTION IN LUPUS NEPHRITIS$294,555
M01 · FY2001 · RR
THREE DOSES OF MELOXICAM W/ DICLOFENAC FOR RHEUMATOID ARTHRITIS$294,555
M01 · FY2001 · RR
ORAL CONTRACEPTIVES AND HORMONAL REPLACEMENT IN SLE$190,747
M01 · FY2001 · RR
PRESERVING OVARIAN FUNCTION IN LUPUS NEPHRITIS$190,747
M01 · FY2001 · RR
THREE DOSES OF MELOXICAM W/ DICLOFENAC FOR RHEUMATOID ARTHRITIS$190,747
M01 · FY2001 · RR
RO32 3555 AS ADJUNCT TO BACKGROUND THERAPY IN RHEUMATOID ARTHRITIS$190,747
M01 · FY2001 · RR
THREE DOSES OF MELOXICAM W/ DICLOFENAC FOR RHEUMATOID ARTHRITIS$294,555
M01 · FY2000 · RR
THREE DOSES OF MELOXICAM W/ DICLOFENAC FOR RHEUMATOID ARTHRITIS$294,555
M01 · FY2000 · RR
THREE DOSES OF MELOXICAM W/ DICLOFENAC FOR RHEUMATOID ARTHRITIS$294,555
M01 · FY2000 · RR
LUPUS NEPHRITIS: ROLE OF ENVIORM. &OCCUPATIONAL EXP.$100,000
R55 · FY2000 · AR
THREE DOSES OF MELOXICAM W/ DICLOFENAC FOR RHEUMATOID ARTHRITIS$241
M01 · FY2000 · RR
RO32 3555 AS ADJUNCT TO BACKGROUND THERAPY IN RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
RO32 3555 AS ADJUNCT TO BACKGROUND THERAPY IN RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
ORAL CONTRACEPTIVES AND HORMONAL REPLACEMENT IN SLE$0
M01 · FY2000 · RR
RO32 3555 AS ADJUNCT TO BACKGROUND THERAPY IN RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
PRESERVING OVARIAN FUNCTION IN LUPUS NEPHRITIS$0
M01 · FY2000 · RR
RO32 3555 AS ADJUNCT TO BACKGROUND THERAPY IN RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
IDEC-131 IN PTS W/ ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2000 · RR